This study addressed respiratory syncytial virus (RSV) infection during pregnancy ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2018
• November 2018

The Telethon Kids Institute is looking for healthy babies (born from 35 weeks of pregnancy onwards) to take part in an important study evaluating a ...

• Wesfarmers Centre of Vaccines & Infectious Diseases
• Our research
• Vaccine Trials Group
• Current studies

Respiratory syncytial virus (RSV) seasonality is dependent on the local climate. We assessed the stability of RSV seasonality prior to the SARS-CoV-2 pandemic in Western Australia (WA), a state spanning temperate and tropical regions. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• March 2023

A multi-country randomized, placebo-controlled trial of the safety, immunogenicity and efficacy of respiratory syncytial virus (RSV) F-protein nanoparticle vaccine was undertaken in 4,636 pregnant women and their infants. RSV F-protein vaccine was safe and immunogenic in the pregnant women inducing anti-F IgG, palivizumab-competing antibodies and RSV neutralizing antibodies that were transferred to the fetus. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• July 2020

The results suggest that though the risk for RSV in the NICU remains low, personnel clothing are contaminated with RSV-RNA and may have a role in transmission ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2016
• January 2016

Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021) RSV seasons have been minimal. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• July 2023

To determine the potential longer-term effects of maternal antenatal respiratory syncytial virus (RSV) vaccination, we examined the association between cord-blood RSV-neutralizing antibodies (RSV-NA) and RSV infections in the first 2 years of life, RSV-NA at 3 years, and respiratory health to age 5 years. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• September 2021

Respiratory syncytial virus (RSV) and influenza are important causes of disease in children and adults. In Australia, information on the burden of RSV in adults is particularly limited. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• June 2022

Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infection in young children. We previously estimated that in 2015, 33·1 million episodes of RSV-associated acute lower respiratory infection occurred in children aged 0-60 months, resulting in a total of 118 200 deaths worldwide. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• May 2022

The transmission dynamics of RSV infection among young children are still poorly understood and mathematical modelling can be used to better understand... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2013
• December 2013